Allakos, Inc.

47 articles with Allakos, Inc.

• Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

  5/6/2022

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

• Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

• Allakos to Host Investor Day on February 15

  2/1/2022

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, announced that it will host an Investor Day on February 15th starting at 8:00 am ET.

• 

  Allakos Reports Mixed Results for Two Eosinophilic GI Disease Studies

  12/22/2021

  Allakos reported mixed results on two clinical trials, the Phase II ENIGMA 2 and Phase II/III KRYPTOS trials of lirentelimab.

• Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

  12/21/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab.

• Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

  11/30/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced it has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis.

• Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

  11/8/2021

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

• Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

  10/25/2021

  Allakos Inc. today announced that its poster, “High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unexplained Gastrointestinal Symptoms,” received a Presidential Poster Award at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting.

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

  10/24/2021

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell related diseases, announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology Annual Scientific Meeting.

• Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

  8/9/2021

  Allakos Inc.Allakos Inc.Allakos Inc.Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, provided a business update and reported financial results for the second quarter ended June 30, 2021.

• New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

  5/24/2021

  45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD)

• Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, reported financial results for the first quarter ended March 31, 2021 and provided a business update.

• Allakos Appoints Baird Radford as Chief Financial Officer

  4/19/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer.

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

  3/30/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting

• Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/1/2021

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

• Allakos Appoints Natalie Holles to its Board of Directors

  12/22/2020

  Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide

• Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

  11/2/2020

  Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting.

• Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

  10/27/2020

  Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The preliminary financial results are subject to finalization of the Company’s customary quarterly financial close process. Allakos estimates that net loss will be between $40.0 million and $50.0 million fo

• Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed

  10/26/2020

  45% (181/405) ofsymptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis

• Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

  10/26/2020

  Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustainedeosinophil suppressionsupporting once monthly dosing